Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2024-03-27 Capital/Financing Update
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SOFTX; Key information relating to the repair issue to be carried out by Softox Solutions AS
Capital/Financing Update Classification · 98% confidence The document explicitly details key information regarding a 'repair issue' (likely a rights issue or capital restructuring event) for Softox Solutions AS. It lists specific dates (announcement date, ex-date, record date), the maximum number of new shares (125,000,000), and the subscription price (NOK 0.2). This content directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release, an annual report, or a simple announcement of a report publication.
2024-03-27 English
SOFTX; Update regarding the financial situation in Softox Solutions AS,
Capital/Financing Update Classification · 98% confidence The document announces the successful completion of a private placement and a debt conversion, resulting in the issuance of new shares and an increase in share capital. It details the gross proceeds raised (NOK 22,329,371), the subscription price (NOK 0.2 per share), and the expected settlement dates. It also mentions that these actions are subject to approval by an Extraordinary General Meeting (EGM) and outlines plans for a subsequent offering. These activities—raising capital through share issuance (private placement and debt-to-equity conversion) and subsequent offering plans—fall directly under the definition of Capital/Financing Update.
2024-03-27 English
SOFTX; Fourth quarter 2023 report and investor deck used in MNOK 25 fund raising March 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report Q4 2023' and contains comprehensive financial statements, including operating revenue, expenses, and cash flow for the period ending December 31, 2023. It also provides detailed management commentary on business strategy, restructuring, and future outlook. As it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q4 2023
2024-03-20 English
SOFTX; Fourth quarter 2023 report and investor deck used in MNOK 25 fund raising March 2024
Investor Presentation Classification · 98% confidence The document explicitly states in the title and throughout the text that it is an "Investor presentation" dated "March 2024". It contains detailed slides covering company strategy (splitting the company), focus areas (VAP), scientific background (HOCl), project plans, and toxicology data tables. This structure and content strongly align with the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position.
2024-03-20 English
SOFTX; Fourth quarter 2023 report and investor deck used in MNOK 25 fund raising March 2024
Report Publication Announcement Classification · 99% confidence The document text explicitly mentions providing the 'fourth quarter 2023 report and March 2024 investor presentation deck' and states that the company 'plan to call for a digital fourth quarter investor presentation soon'. Since the document itself is very short (1331 chars) and its primary function is to announce the availability of these materials (the report and the deck) rather than being the full report or presentation itself, it fits the definition of a Report Publication Announcement (RPA). The mention of an 'investor deck' also strongly suggests an investor-facing communication about published materials.
2024-03-20 English
SOFTX: Call for extraordinary general assembly the 27th of March 2024
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of an extraordinary general meeting of Softox Solutions AS" and details the agenda, proposed resolutions (including capital increases, debt conversion, and issuance of warrants), date (27th of March 2024), and location for an Extraordinary General Meeting (EGM). This content directly relates to the formal proceedings and proposals presented to shareholders for a general meeting. Although it discusses capital changes (CAP) and warrants (which could relate to SHA), the primary function and structure of the document is the notice and agenda for the meeting itself. This aligns best with the definition of AGM Information (AGM-R), which covers presentations and materials shared during General Meetings (including Extraordinary General Meetings).
2024-03-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.